financetom
Business
financetom
/
Business
/
US-blacklisted Zhipu AI gets fresh funding from Chinese state firm
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US-blacklisted Zhipu AI gets fresh funding from Chinese state firm
Mar 13, 2025 1:57 AM

BEIJING (Reuters) - Chinese AI startup Zhipu AI secured 500 million yuan ($69.04 million) in funding from state-owned Huafa Group, just one week after announcing a separate 1 billion yuan capital raise.

Huafa Group, a state conglomerate based in Zhuhai in Guangdong province, announced its investment in Zhipu in a statement on Wednesday, as Chinese cities compete to back promising AI startups in a sector Beijing views as crucial in its technology rivalry with the United States.

This comes after Hangzhou, home to rival DeepSeek, was among the major investors in a 1 billion-yuan funding round announced earlier this month through state-backed entity Hangzhou City Investment Group Industrial Fund.

The funding follows the recent emergence of rival DeepSeek, whose large language models have garnered attention for purportedly matching Western competitors' capabilities at lower develoment costs.

Zhipu AI, founded in 2019 and widely known as one of China's "AI tigers," has attracted investment from tech giants Tencent, Meituan and Xiaomi across more than 15 funding rounds, according to business registration platform Qichacha.

The company was valued at 20 billion yuan in a funding round in July 2024, according to business registration platform Qichacha.

The new capital will be used to advance technological innovation and ecosystem development of its GLM foundation model, Huafa said in the statement.

In January, Zhipu and its subsidiaries were added to the U.S. Commerce Department's export control entity list, barring it to procure U.S. components.

($1 = 7.2417 Chinese yuan renminbi)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Datadog Insider Sold Shares Worth $10,273,557, According to a Recent SEC Filing
Datadog Insider Sold Shares Worth $10,273,557, According to a Recent SEC Filing
Nov 5, 2025
04:35 PM EST, 11/05/2025 (MT Newswires) -- Olivier Pomel, Director, Chief Executive Officer, on November 03, 2025, sold 62,682 shares in Datadog ( DDOG ) for $10,273,557. Following the Form 4 filing with the SEC, Pomel has control over a total of 533,358 Class A common shares of the company, with 533,358 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1561550/000156155025000305/xslF345X05/wk-form4_1762376488.xml ...
Blue Owl Capital Corporation and Blue Owl Capital Corporation II Announce Merger Agreement
Blue Owl Capital Corporation and Blue Owl Capital Corporation II Announce Merger Agreement
Nov 5, 2025
Merger of two high-quality, diversified portfolios with substantial investment overlap that enhances scale Will strengthen OBDC's position as the second largest publicly traded BDC by total assets1 NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Blue Owl Capital Corporation ( OBDC ) and Blue Owl Capital Corporation II (OBDC II) announced today that they have entered into a definitive merger agreement,...
Cloud computing firm Fastly beats Q3 revenue estimates
Cloud computing firm Fastly beats Q3 revenue estimates
Nov 5, 2025
Overview * Fastly Q3 revenue of $158.2 mln beats analyst expectations * Company reports non-GAAP net income per share of $0.08, up from $0.03 last year * Security revenue grows 30% yr/yr, driven by strong cross-sell execution Outlook * Company expects Q4 2025 revenue between $159 mln and $163 mln * Fastly projects full-year 2025 revenue between $610 mln and...
Aquestive Therapeutics misses Q3 revenue, beats adjusted EBITDA estimates
Aquestive Therapeutics misses Q3 revenue, beats adjusted EBITDA estimates
Nov 5, 2025
Overview * Aquestive Q3 revenue misses analyst expectations, but adjusted EBITDA beats estimates * Company prepares for potential U.S. launch of Anaphylm in Q1 2026, pending FDA approval * Aquestive strengthens balance sheet to support Anaphylm launch Outlook * Company expects FY revenue of $44 mln to $50 mln * Aquestive expects FY adjusted EBITDA loss of $47 mln to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved